Pediatric allergic rhinitis and asthma: Can the march be halted?

Pediatric Drugs

Volumn 15, Issue 6, 2013, Pages 431-440

  Tsilochristou, Olympia A ^a   Douladiris, Nikolaos ^b   Makris, Michael ^a   Papadopoulos, Nikolaos G ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; HOUSE DUST ALLERGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LORATADINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEPOLIZUMAB; MONTELUKAST; NITRIC OXIDE; OMALIZUMAB; PITRAKINRA; PROBIOTIC AGENT;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CHILDHOOD DISEASE; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; LONGITUDINAL STUDY; LUNG FUNCTION; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOCONJUNCTIVITIS; SECONDARY PREVENTION; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW (TOPIC); TH1 CELL; TREATMENT OUTCOME; UPREGULATION;

ADOLESCENT; ASTHMA; CHILD; DISEASE PROGRESSION; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOTHERAPY; PREVALENCE; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84890491762     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0043-3     Document Type: Review

References (112)

1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8-160. doi: 10.1111/j.1398-9995.2007.01620.x.
2. Grossman J. One airway, one disease. Chest. 1997;111(2 Suppl):11S-6S.
3. Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol. 1999;104(3 Pt 1):534-40.
4. Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol. 2001;1(1):7-13.
5. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol. 2003;111(6):1171-83 quiz 84.
6. Papadopoulos NG, Borres M, Gern J, Nieto A. New visions in respiratory allergy (asthma and allergic rhinitis): an iPAC summary and future trends. Pediatr Allergy Immunol. 2008;19(Suppl 19):51-9. doi: 10.1111/j.1399-3038.2008. 00767.x.
7. Leynaert B, Neukirch C, Kony S, Guenegou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004;113(1):86-93. doi: 10.1016/j.jaci.2003.10.010.
8. Pedersen PA, Weeke ER. Asthma and allergic rhinitis in the same patients. Allergy. 1983;38(1):25-9.
9. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111):1225-32.
10. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J. 1998;12(2):315-35.
11. Grize L, Gassner M, Wuthrich B, Bringolf-Isler B, Takken-Sahli K, Sennhauser FH, et al. Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001. Allergy. 2006;61(5):556-62. doi: 10.1111/j.1398-9995.2006.01030.x.
12. Westman M, Stjarne P, Asarnoj A, Kull I, van Hage M, Wickman M, et al. Natural course and comorbidities of allergic and nonallergic rhinitis in children. J Allergy Clin Immunol. 2012;129(2):403-8. doi: 10.1016/j.jaci.2011. 09.036.
13. Chawes BL, Bonnelykke K, Kreiner-Moller E, Bisgaard H. Children with allergic and nonallergic rhinitis have a similar risk of asthma. J Allergy Clin Immunol. 2010;126(3):567-73 e1-8. doi: 10.1016/j.jaci.2010.06.026.
14. Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics. 1994;94(6 Pt 1):895-901.
15. Thomas M, Kocevar VS, Zhang Q, Yin DD, Price D. Asthma-related health care resource use among asthmatic children with and without concomitant allergic rhinitis. Pediatrics. 2005;115(1):129-34. doi: 10.1542/peds.2004-0067.
16. Sazonov Kocevar V, Thomas J 3rd, Jonsson L, Valovirta E, Kristensen F, Yin DD, et al. Association between allergic rhinitis and hospital resource use among asthmatic children in Norway. Allergy. 2005;60(3):338-42. doi: 10.1111/j.1398-9995.2005.00712.x.
17. Burgess JA, Walters EH, Byrnes GB, Matheson MC, Jenkins MA, Wharton CL, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120(4):863-9. doi: 10.1016/j.jaci.2007.07.020.
18. Van Cauwenberge P, Watelet JB, Van Zele T, Wang DY, Toskala E, Durham S, et al. Does rhinitis lead to asthma? Rhinology. 2007;45(2):112-21.
19. Georgalas C, Terreehorst I, Fokkens W. Current management of allergic rhinitis in children. Pediatr Allergy Immunol. 2010;21(1 Pt 2):e119-26. doi: 10.1111/j.1399-3038.2009.00934.x.
20. Caimmi D, Marseglia A, Pieri G, Benzo S, Bosa L, Caimmi S. Nose and lungs: one way, one disease. Ital J Pediatr. 2012;38:60. doi: 10.1186/1824-7288-38-60.
21. Braunstahl GJ. The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J Allergy Clin Immunol. 2005;115(1):142-8. doi: 10.1016/j.jaci.2004.10.041.
22. Denburg JA, Keith PK. Eosinophil progenitors in airway diseases: clinical implications. Chest. 2008;134(5):1037-43. doi: 10.1378/chest.08-0485.
23. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol. 2001;107(3):469-76. doi: 10.1067/mai.2001.113046.
24. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med. 2000;161(6):2051-7. doi: 10.1164/ajrccm.161.6.9906121.
25. Braunstahl GJ, Overbeek SE, Fokkens WJ, Kleinjan A, McEuen AR, Walls AF, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med. 2001;164(5):858-65. doi: 10.1164/ajrccm.164.5.2006082.
26. Chanez P, Vignola AM, Vic P, Guddo F, Bonsignore G, Godard P, et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am J Respir Crit Care Med. 1999;159(2):588-95. doi: 10.1164/ajrccm.159.2.9801022.
27. Suh DI, Lee JK, Kim JT, Min YG, Koh YY. Bronchial hyperresponsiveness in preschool children with allergic rhinitis. Am J Rhinol Allergy. 2011;25(5):e186-90. doi: 10.2500/ajra.2011.25.3685.
28. Choi SH, Yoo Y, Yu J, Rhee CS, Min YG, Koh YY. Bronchial hyperresponsiveness in young children with allergic rhinitis and its risk factors. Allergy. 2007;62(9):1051-6. doi: 10.1111/j.1398-9995.2007.01403.x.
29. Cuttitta G, Cibella F, La Grutta S, Hopps MR, Bucchieri S, Passalacqua G, et al. Non-specific bronchial hyper-responsiveness in children with allergic rhinitis: relationship with the atopic status. Pediatr Allergy Immunol. 2003;14(6):458-63.
30. Linhares D, Jacinto T, Pereira AM, Fonseca JA. Effects of atopy and rhinitis on exhaled nitric oxide values - a systematic review. Clin Transl Allergy. 2011;1(1):8. doi: 10.1186/2045-7022-1-8.
31. Tamari M, Tanaka S, Hirota T. Genome-wide association studies of allergic diseases. Allergol Int. 2013;62(1):21-8. doi: 10.2332/allergolint.13-RAI-0539.
32. Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy. 2009;64(1):81-4. doi: 10.1111/j.1398-9995.2008.01846.x.
33. Thomas M. Allergic rhinitis: evidence for impact on asthma. BMC Pulm Med. 2006;6(Suppl 1):S4. doi: 10.1186/1471-2466-6-S1-S4.
34. Calderon MA, Gerth van Wijk R, Eichler I, Matricardi PM, Varga EM, Kopp MV, et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol. 2012;23(4):300-6. doi: 10.1111/j.1399-3038.2012.01313.x.
35. Nurmatov U, van Schayck CP, Hurwitz B, Sheikh A. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012;67(2):158-65. doi: 10.1111/j.1398-9995.2011. 02752.x.
36. Wood RA, Johnson EF, Van Natta ML, Chen PH, Eggleston PA. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998;158(1):115-20.
37. Bjornsdottir US, Jakobinudottir S, Runarsdottir V, Juliusson S. The effect of reducing levels of cat allergen (Fel d 1) on clinical symptoms in patients with cat allergy. Ann Allergy Asthma Immunol. 2003;91(2):189-94.
38. Ciprandi G, Ricca V, Tosca M, Landi M, Passalacqua G, Canonica GW. Continuous antihistamine treatment controls allergic inflammation and reduces respiratory morbidity in children with mite allergy. Allergy. 1999;54(4):358-65.
39. Ciprandi G, Tosca M, Ricca V, Passalacqua G, Riccio AM, Bagnasco M, et al. Cetirizine treatment of rhinitis in children with pollen allergy: evidence of its antiallergic activity. Clin Exp Allergy. 1997;27(10):1160-6.
40. Vancheri C, Mastruzzo C, Tomaselli V, Bellistri G, Pistorio MP, Greco LR, et al. The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc. 2005;26(4):292-8.
41. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1998;101(3):410-20. doi: 10.1016/S0091- 6749(98)70256-8.
42. Grant JA, Nicodemus CF, Findlay SR, Glovsky MM, Grossman J, Kaiser H, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1995;95(5 Pt 1):923-32.
43. Corren J, Harris AG, Aaronson D, Beaucher W, Berkowitz R, Bronsky E, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol. 1997;100(6 Pt 1):781-8.
44. Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J. 1997;10(10):2216-24.
45. Rédier H, Chanez P, De Vos C, Rifaï N, Clauzel AM, Michel FB, et al. Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma. J Allergy Clin Immunol. 1992;90(2):215-24.
46. Warner JO. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol. 2001;108(6):929-37. doi: 10.1067/mai.2001.120015.
47. Iikura Y, Naspitz CK, Mikawa H, Talaricoficho S, Baba M, Sole D, et al. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy. 1992;68(3):233-6.
48. Bustos GJ, Bustos D, Romero O. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study. Clin Exp Allergy. 1995;25(6):568-73.
49. Warner JO. Future aspects of pharmacological treatment to inhibit the allergic march. Pediatr Allergy Immunol. 2001;12(Suppl 14):102-7.
50. Simons FE. Safety of levocetirizine treatment in young atopic children: an 18-month study. Pediatr Allergy Immunol. 2007;18(6):535-42. doi: 10.1111/j.1399-3038.2007.00558.x.
51. O'Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol. 2011;128(6):1153-62. doi: 10.1016/j.jaci.2011.06.051.
52. Gibbs BF, Levi-Schaffer F. H(4) receptors in mast cells and basophils: a new therapeutic target for allergy? Front Biosci. 2012;17:430-7.
53. Shiraishi Y, Jia Y, Domenico J, Joetham A, Karasuyama H, Takeda K, et al. Sequential engagement of FcεRI on mast cells and basophil histamine H(4) receptor and FcεRI in allergic rhinitis. J Immunol. 2013;190(2):539-48. doi: 10.4049/jimmunol.1202049.
54. Murphy K, Uryniak T, Simpson B, O'Dowd L. Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol. 2006;96(5):723-30. doi: 10.1016/S1081-1206(10)61072- 1.
55. Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23(6):407-13.
56. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22.
57. Taramarcaz P, Gibson PG. The effectiveness of intranasal corticosteroids in combined allergic rhinitis and asthma syndrome. Clin Exp Allergy. 2004;34(12):1883-9. doi: 10.1111/j.1365-2222.2004.02130.x.
58. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy. 2013;68(5):569-79. doi: 10.1111/all.12124.
59. Ozturk F, Turktas I, Asal K, Ileri F, Munevver Pinar N. Effect of intranasal triamcinolone acetonide on bronchial hyper-responsiveness in children with seasonal allergic rhinitis and comparison of perceptional nasal obstruction with acoustic rhinometric assessment. Int J Pediatr Otorhinolaryngol. 2004;68(8):1007-15. doi: 10.1016/j.ijporl.2004.03.006.
60. Thio BJ, Slingerland GL, Fredriks AM, Nagelkerke AF, Scheeren RA, Neijens HJ, et al. Influence of intranasal steroids during the grass pollen season on bronchial responsiveness in children and young adults with asthma and hay fever. Thorax. 2000;55(10):826-32.
61. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol. 2002;109(4):636-42.
62. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol. 1993;91(1 Pt 1):97-101.
63. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol. 1998;101(2 Pt 2):S352-6.
64. Pedersen W, Hjuler I, Bisgaard H, Mygind N. Nasal inhalation of budesonide from a spacer in children with perennial rhinitis and asthma. Allergy. 1998;53(4):383-7.
65. Camargos PA, Rodrigues ME, Lasmar LM. Simultaneous treatment of asthma and allergic rhinitis. Pediatr Pulmonol. 2004;38(3):186-92. doi: 10.1002/ppul.20084.
66. Camargos P, Ibiapina C, Lasmar L, Cruz AA. Obtaining concomitant control of allergic rhinitis and asthma with a nasally inhaled corticosteroid. Allergy. 2007;62(3):310-6. doi: 10.1111/j.1398-9995.2007.01241.x.
67. Ribeiro de Andrade C, Chatkin JM, Fiterman J, Scaglia N, Camargos PA. Unified disease, unified management: treating allergic rhinitis and asthma with nasally inhaled corticosteroid. Respir Med. 2010;104(10):1577-80. doi: 10.1016/j.rmed.2010.06.021.
68. Greiff L, Andersson M, Svensson C, Linden M, Wollmer P, Brattsand R, et al. Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J. 1998;11(6):1268-73.
69. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006;368(9537):754-62. doi: 10.1016/S0140-6736(06)69285-4.
70. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985-97. doi: 10.1056/NEJMoa051378.
71. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med. 2006;354(19):1998-2005. doi: 10.1056/NEJMoa054692.
72. Mygind N, Laursen LC, Dahl M. Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. Allergy. 2000;55(1):11-5.
73. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012;129(5):1282-9 e10. doi: 10.1016/j.jaci.2012.01.077.
74. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116(5):338-44. doi: 10.1016/j.amjmed.2003.10.030.
75. Rodrigo GJ, Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96(6):779-86. doi: 10.1016/S1081-1206(10)61339-7.
76. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007;67(6):887-901.
77. Li AM, Abdullah VJ, Tsen CS, Au CT, Lam HS, So HK, et al. Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis - a randomized placebo-controlled study. Pediatr Pulmonol. 2009;44(11):1085-92. doi: 10.1002/ppul.21102.
78. Razi C, Bakirtas A, Harmanci K, Turktas I, Erbas D. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(6):767-74. doi: 10.1016/S1081-1206(10)60968-4.
79. Papadopoulos NG, Philip G, Giezek H, Watkins M, Smugar SS, Polos PG. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009;46(4):413-20. doi: 10.1080/02770900902847727.
80. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008;178(8):854-60. doi: 10.1164/rccm.200706-910OC.
81. Walker SM, Durham SR, Till SJ, Roberts G, Corrigan CJ, Leech SC, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011;41(9):1177-200. doi: 10.1111/j.1365-2222.2011.03794.x.
82. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943-8. doi: 10.1111/j.1398-9995.2007.01451.x.
83. Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Host A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855-9. doi: 10.1111/j.1398-9995.2006.01068.x.
84. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251-6.
85. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003;33(2):206-10.
86. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851-7. doi: 10.1016/j.jaci.2004.07.012.
87. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15(1):9-16.
88. Papadopoulos NG, Agache I, Bavbek S, Bilo BM, Braido F, Cardona V, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy. 2012;2(1):21. doi: 10.1186/2045-7022-2-21.
89. Valovirta E, Berstad AK, de Blic J, Bufe A, Eng P, Halken S, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther. 2011;33(10):1537-46. doi: 10.1016/j.clinthera.2011.09.013.
90. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006;55(4):379-86. doi: 10.2332/allergolint.55.379.
91. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286(23):2956-67.
92. Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24(5):323-9.
93. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106(2):253-9. doi: 10.1067/mai.2000.108310.
94. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(2):160-7. doi: 10.1016/S1081-1206(10)62171-0.
95. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274-80.
96. Rolinck-Werninghaus C, Hamelmann E, Keil T, Kulig M, Koetz K, Gerstner B, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004;59(9):973-9. doi: 10.1111/j.1398-9995.2004.00552.x.
97. Kopp MV, Stenglein S, Kamin W, Friedrichs F, von Berg A, Zielen S, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol. 2007;18(6):523-7. doi: 10.1111/j.1399-3038.2007.00557. x.
98. Kopp MV, Brauburger J, Riedinger F, Beischer D, Ihorst G, Kamin W, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;110(5):728-35.
99. Bez C, Schubert R, Kopp M, Ersfeld Y, Rosewich M, Kuehr J, et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin Exp Allergy. 2004;34(7):1079-85. doi: 10.1111/j.1365-2222.2004.01998.x.
100. Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma. 2011;48(4):387-92. doi: 10.3109/02770903.2011.561512.
101. Nopp A, Johansson SG, Ankerst J, Palmqvist M, Oman H. CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy. 2007;62(10):1175-81. doi: 10.1111/j.1398-9995.2007.01476.x.
102. Cox LS. How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol. 2009;5(1):4. doi: 10.1186/1710-1492-5-4.
103. Robinson DS. Mepolizumab for severe eosinophilic asthma. Expert Rev Respir Med. 2013;7(1):13-7. doi: 10.1586/ers.12.84.
104. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.
105. Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113(1):115-9. doi: 10.1016/j.jaci.2003.10.049.
106. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989-95 e1-8. doi: 10.1016/j.jaci.2011.07.056.
107. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596):1422-31. doi: 10.1016/S0140-6736(07)61600-6.
108. Giovannini M, Agostoni C, Riva E, Salvini F, Ruscitto A, Zuccotti GV, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res. 2007;62(2):215-20. doi: 10.1203/PDR.0b013e3180a76d94.
109. Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol. 2005;16(5):433-8. doi: 10.1111/j.1399-3038.2005. 00284.x.
110. Ciprandi G, Vizzaccaro A, Cirillo I, Tosca MA. Bacillus clausii effects in children with allergic rhinitis. Allergy. 2005;60(5):702-3. doi: 10.1111/j.1398-9995.2005.00722.x.
111. Ivory K, Chambers SJ, Pin C, Prieto E, Arques JL, Nicoletti C. Oral delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses in allergic rhinitis. Clin Exp Allergy. 2008;38(8):1282-9. doi: 10.1111/j.1365-2222.2008.03025.x.
112. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for the treatment of eczema: a systematic review. Clin Exp Allergy. 2009;39(8):1117-27. doi: 10.1111/j.1365-2222.2009.03305.x.